

WEST Search History

DATE: Thursday, August 15, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L9	immunomodulat\$ same (oleic adj1 acid)	2	L9
L8	immunomodulat\$ adj5 (oleic acid\$)	76	L8
L7	immunomodulat\$ same (oleic acid\$)	1246	L7
L6	oleic same vaccine\$	26	L6
L5	oleic adj1 acid same vaccine\$	21	L5
L4	monoglyceride\$ same vaccine\$	5	L4
L3	monoglyceride\$ adj10 vaccine\$	0	L3
L2	monoglyceride\$ adj10 adjuvant\$	16	L2
L1	monoglyceride\$ adj5 adjuvant\$	12	L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 12 of 12 returned.**☐ 1. Document ID: US 5143671 A

L1: Entry 1 of 12

File: USPT

US-PAT-NO: 5143671

DOCUMENT-IDENTIFIER: US 5143671 A

TITLE: Fluidized bed process for treating pigments

DATE-ISSUED: September 1, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Peters; Kimberly T.	Johnson City	TN		
Smith; E. Phillip	Blountville	TN		
Kirk; Shane K.	Church Hill	TN		

US-CL-CURRENT: 264/117; 106/503, 23/313FB, 427/213

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 2. Document ID: US 4867899 A

L1: Entry 2 of 12

File: USPT

US-PAT-NO: 4867899

DOCUMENT-IDENTIFIER: US 4867899 A

TITLE: Sodium monoglyceride sulfate detergent composition bar and process for manufacture thereof

DATE-ISSUED: September 19, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ahmed; Fahim U.	Dayton	NJ		
Gabor; Thomas J.	Forest Hills	NY		
Muller; Ernest G.	Piscataway	NJ		
Subramanyam; Ravi	Perth Amboy	NJ		

US-CL-CURRENT: 510/153; 510/294, 510/484, 510/491, 510/495

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 3. Document ID: US 4252827 A

L1: Entry 3 of 12

File: USPT

US-PAT-NO: 4252827

DOCUMENT-IDENTIFIER: US 4252827 A

TITLE: Oxygen-transferable fluorocarbon emulsion

DATE-ISSUED: February 24, 1981

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yokoyama; Kazumasa	Suita			JP
Yamanouchi; Kouichi	Sakai			JP
Murashima; Ryoichiro	Kashihara			JP
Tsuda; Yoshio	Kyoto			JP

US-CL-CURRENT: 514/776; 514/772, 514/781, 514/784, 514/937, 514/941, 514/943

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 4. Document ID: US 3993581 A

L1: Entry 4 of 12

File: USPT

US-PAT-NO: 3993581

DOCUMENT-IDENTIFIER: US 3993581 A

TITLE: Process for preparing stable oxygen transferable emulsion

DATE-ISSUED: November 23, 1976

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yokoyama; Kazumasa	Suita			JA
Yamanouchi; Koichi	Sakai			JA
Murashima; Ryoichiro	Kashihara			JA
Watanabe; Ryoza	Takatsuki			JA

US-CL-CURRENT: 516/56; 514/747, 516/DIG.6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 5. Document ID: US 3962439 A

L1: Entry 5 of 12

File: USPT

US-PAT-NO: 3962439

DOCUMENT-IDENTIFIER: US 3962439 A

TITLE: Oxygen-transferable emulsion

DATE-ISSUED: June 8, 1976

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yokoyama; Kazumasa	Suita			JA
Yamanouchi; Koichi	Sakai			JA
Murashima; Ryoichiro	Kashihara			JA
Watanabe; Ryoza	Takatsuki			JA

US-CL-CURRENT: 514/231.2, 514/315, 514/451, 514/461, 514/579, 514/672, 514/722,
514/756, 514/759, 514/832

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 6. Document ID: JP 58032829 A JP 58032829 A

L1: Entry 6 of 12

File: JPAB

Feb 25, 1983

PUB-NO: JP358032829A

DOCUMENT-IDENTIFIER: JP 58032829 A

TITLE: CONTRAST MEDIUM FOR BLOOD VESSEL

PUBN-DATE: February 25, 1983

INVENTOR-INFORMATION:

NAME	COUNTRY
YOKOYAMA, KAZUMASA	
TSUDA, YOSHIO	
MURASHIMA, RYOICHIRO	

US-CL-CURRENT: 424/9.4, 424/900, 424/9.4, 424/900
INT-CL (IPC): A61K 49/04

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 7. Document ID: WO 9902186 A2 WO 9902186 A2

L1: Entry 7 of 12

File: EPAB

Jan 21, 1999

PUB-NO: WO009902186A2

DOCUMENT-IDENTIFIER: WO 9902186 A2

TITLE: ANTIGEN DELIVERY SYSTEM COMPRISING MONOGLYCERIDE OR DIGLYCERIDE DERIVATIVES AS ADJUVANT

PUBN-DATE: January 21, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
GIZURARSON, SVEINBJOERN	IS
GUDMUNDSDOTTIR, VERA	IS

INT-CL (IPC): A61 K 39/39; A61 K 9/107; A61 K 47/14
EUR-CL (EPC): A61K009/00; A61K009/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KUMC
Draw Desc	Image									

☐ 8. Document ID: US 4252827 A US 4252827 A

L1: Entry 8 of 12

File: EPAB

Feb 24, 1981

PUB-NO: US004252827A
DOCUMENT-IDENTIFIER: US 4252827 A
TITLE: Oxygen-transferable fluorocarbon emulsion

PUBN-DATE: February 24, 1981

INVENTOR-INFORMATION:

NAME	COUNTRY
YOKOYAMA, KAZUMASA	
YAMANOUCHI, KOUICHI	
MURASHIMA, RYOICHIRO	
TSUDA, YOSHIO	

INT-CL (IPC): A61K 45/00
EUR-CL (EPC): A61K009/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KUMC
Draw Desc	Image									

☐ 9. Document ID: US 3993581 A US 3993581 A

L1: Entry 9 of 12

File: EPAB

Nov 23, 1976

PUB-NO: US003993581A
DOCUMENT-IDENTIFIER: US 3993581 A
TITLE: Process for preparing stable oxygen transferable emulsion

PUBN-DATE: November 23, 1976

INVENTOR-INFORMATION:

NAME	COUNTRY
YOKOYAMA, KAZUMASA	
YAMANOUCHI, KOICHI	
MURASHIMA, RYOICHIRO	
WATANABE, RYOZO	

INT-CL (IPC): B01J 13/00
EUR-CL (EPC): A61K009/00; A61K031/02

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 10. Document ID: US 3962439 A US 3962439 A

L1: Entry 10 of 12

File: EPAB

Jun 8, 1976

PUB-NO: US003962439A

DOCUMENT-IDENTIFIER: US 3962439 A

TITLE: Oxygen-transferable emulsion

PUBN-DATE: June 8, 1976

INVENTOR-INFORMATION:

NAME

COUNTRY

YOKOYAMA, KAZUMASA

YAMANOUCHI, KOICHI

MURASHIMA, RYOICHIRO

WATANABE, RYOZO

INT-CL (IPC): A61K 31/535; A61K 31/445; A61K 31/335; A61K 31/35

EUR-CL (EPC): A61K031/02; A61K009/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 11. Document ID: EP 1150713 A2 WO 200047224 A2 AU 200025473 A

L1: Entry 11 of 12

File: DWPI

Nov 7, 2001

DERWENT-ACC-NO: 2000-549085

DERWENT-WEEK: 200168

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Tuberculosis (TB) vaccine compositions comprising monoglycerides and fatty acids as adjuvants, useful for mucosal immunization against TB

INVENTOR: SCHROEDER, U; SVENSON, S

PRIORITY-DATA: 1999SE-0000496 (February 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1150713 A2	November 7, 2001	E	000	A61K039/39
WO 200047224 A2	August 17, 2000	E	014	A61K039/00
AU 200025473 A	August 29, 2000		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/385; A61 K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Clip Img	Image							

KVMC

☐ 12. Document ID: EP 1154792 A2 WO 200047225 A2 AU 200028035 A

L1: Entry 12 of 12

File: DWPI

Nov 21, 2001

DERWENT-ACC-NO: 2000-532973

DERWENT-WEEK: 200176

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Tuberculosis (TB) vaccine compositions comprising monoglycerides and fatty acids as adjuvants

INVENTOR: SCHROEDER, U; SVENSON, S

PRIORITY-DATA: 1999SE-0000495 (February 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1154792 A2	November 21, 2001	E	000	A61K039/39
WO 200047225 A2	August 17, 2000	E	014	A61K039/00
AU 200028035 A	August 29, 2000		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Clip Img	Image								

[Generate Collection](#)[Print](#)

Terms	Documents
monoglyceride\$ adj5 adjuvant\$	12

Display Format: [Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 5 of 5 returned.**☐ 1. Document ID: WO 9747320 A1 WO 9747320 A1

L4: Entry 1 of 5

File: EPAB

Dec 18, 1997

PUB-NO: WO009747320A1

DOCUMENT-IDENTIFIER: WO 9747320 A1

TITLE: IMMUNSTIMULATING LIPID FORMULATION

PUBN-DATE: December 18, 1997

INVENTOR- INFORMATION:

NAME

SCHROEDER, ULF

COUNTRY

SE

INT-CL (IPC): A61 K 39/39; A61 K 47/14EUR-CL (EPC): A61K039/39; A61K009/127, A61K039/05 , A61K039/145 , A61K039/15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMCC
Draw Desc	Image									

☐ 2. Document ID: EP 1150713 A2 WO 200047224 A2 AU 200025473 A

L4: Entry 2 of 5

File: DWPI

Nov 7, 2001

DERWENT-ACC-NO: 2000-549085

DERWENT-WEEK: 200168

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Tuberculosis (TB) vaccine compositions comprising monoglycerides and fatty acids as adjuvants, useful for mucosal immunization against TB

INVENTOR: SCHROEDER, U; SVENSON, S

PRIORITY-DATA: 1999SE-0000496 (February 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1150713 A2	November 7, 2001	E	000	A61K039/39
WO 200047224 A2	August 17, 2000	E	014	A61K039/00
AU 200025473 A	August 29, 2000		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/385; A61 K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMCC
Draw Desc	Clip Img	Image								

☐ 3. Document ID: EP 1154792 A2 WO 200047225 A2 AU 200028035 A

L4: Entry 3 of 5

File: DWPI

Nov 21, 2001

DERWENT-ACC-NO: 2000-532973

DERWENT-WEEK: 200176

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Tuberculosis (TB) vaccine compositions comprising monoglycerides and fatty acids as adjuvants

INVENTOR: SCHROEDER, U; SVENSON, S

PRIORITY-DATA: 1999SE-0000495 (February 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1154792 A2	November 21, 2001	E	000	A61K039/39
WO 200047225 A2	August 17, 2000	E	014	A61K039/00
AU 200028035 A	August 29, 2000		000	A61K039/00

INT-CL (IPC): A61 K 39/00; A61 K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Clip Img	Image								

☐ 4. Document ID: US 2002012673 A1 WO 9747320 A1 AU 9731998 A EP 918541 A1 NZ 333226 A JP 2000512292 W AU 724655 B

L4: Entry 4 of 5

File: DWPI

Jan 31, 2002

DERWENT-ACC-NO: 1998-086552

DERWENT-WEEK: 200210

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Formulation for parenteral or mucosal administration of antigens or vaccines - containing mono:glyceride(s) and fatty acids

INVENTOR: SCHRODER, U; SCHROEDER, U

PRIORITY-DATA: 1996SE-0002280 (June 10, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002012673 A1	January 31, 2002		000	A61K009/00
WO 9747320 A1	December 18, 1997	E	021	A61K039/39
AU 9731998 A	January 7, 1998		000	A61K039/39
EP 918541 A1	June 2, 1999	E	000	A61K039/39
NZ 333226 A	May 26, 2000		000	A61K047/14
JP 2000512292 W	September 19, 2000		021	A61K039/39
AU 724655 B	September 28, 2000		000	A61K039/39

INT-CL (IPC): A61 K 9/00; A61 K 39/39; A61 K 47/12; A61 K 47/14

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 5. Document ID: NO 312057 B1 WO 9417827 A1 AU 9461065 A NO 9503182 A EP 682528 A1 AU 668290 B JP 09508614 W US 5942237 A EP 682528 B1 DE 69425427 E ES 2150982 T3

L4: Entry 5 of 5

File: DWPI

Mar 11, 2002

DERWENT-ACC-NO: 1994-279393

DERWENT-WEEK: 200228

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Topical application of antigens and/or vaccines - using polyoxyethylene sorbitan mono-ester(s), polyoxyethylene castor oil, capr(yl)ic capric acid glyceride(s) or ganglioside(s)

INVENTOR: GIZURARSON, S; HERON, I

PRIORITY-DATA: 1993DK-0000170 (February 15, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
NO 312057 B1	March 11, 2002		000	A61K047/34
WO 9417827 A1	August 18, 1994	E	031	A61K039/39
AU 9461065 A	August 29, 1994		000	A61K039/39
NO 9503182 A	October 12, 1995		000	A61K047/14
EP 682528 A1	November 22, 1995	E	000	A61K039/39
AU 668290 B	April 26, 1996		000	A61K039/39
JP 09508614 W	September 2, 1997		029	A61K039/39
US 5942237 A	August 24, 1999		000	A61K039/39
EP 682528 B1	August 2, 2000	E	000	A61K039/39
DE 69425427 E	September 7, 2000		000	A61K039/39
ES 2150982 T3	December 16, 2000		000	A61K039/39

INT-CL (IPC): A61 K 9/00; A61 K 9/06; A61 K 9/10; A61 K 9/107; A61 K 9/113; A61 K 39/39; A61 K 47/14; A61 K 47/26; A61 K 47/34; A61 K 47/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KOMIC
Draw Desc	Clip Img	Image								

Generate Collection

Print

Terms	Documents
monoglyceride\$ same vaccine\$	5

Display Format: - Change Format

[Previous Page](#)[Next Page](#)

WEST Search History

DATE: Thursday, August 15, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L4	monoglyceride\$ same vaccine\$	5	L4
L3	monoglyceride\$ adj10 vaccine\$	0	L3
L2	monoglyceride\$ adj10 adjuvant\$	16	L2
L1	monoglyceride\$ adj5 adjuvant\$	12	L1

END OF SEARCH HISTORY

WEST

Generate Collection

Print

L6: Entry 17 of 26

File: USPT

DOCUMENT-IDENTIFIER: US 5352450 A

TITLE: Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop

Detailed Description Text (72):

The protective vaccine composition for dental caries of the present invention may further comprise an adjuvant such as alum, aluminum hydroxide, aluminum phosphate, aluminum sulfate and muramyl dipeptide; adjuvant fat-soluble components (agents for accelerating absorption) such as oleic acid, stearic acid and palmitic acid; humectants such as glycerin, sorbite, xylite, mannite, lactite, maltire and polyethylene glycols (such as PEG 400 and PEG 4,000); preservatives such as sorbic acid, chlorobutanol, benzoic acid, o-oxybenzoic acid ester, boric acid, dehydroacetic acid and thymol; and binders such as sodium polyacrylate, polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxy methyl cellulose, methyl cellulose, hydroxyethyl cellulose, carrageenan, sodium alginate, gum arabic, xanthane gum, montmorillonite, kaolin, hydrated silica, aluminum magnesium silicate and hectorite.

WEST



Generate Collection

Print

L6: Entry 16 of 26

File: USPT

DOCUMENT-IDENTIFIER: US 5424067 A

TITLE: Injectable multi-phase emulsions

Detailed Description Text (38):

Test according to the protocols described in the European Pharmacopeia have shown that there was no abnormal toxicity in the placebo vaccines according to the invention, in particular those prepared from oleic esters of mannitol and of PEG, and from fluid mineral oil or polyisobutylene synthetic oil.

Detailed Description Paragraph Table (2):

<p>TABLE 1 - 1</p> <p>OF THE BSA VACCINE</p> <p>adjuvant ASPECT clear oil of straw yellow color</p> <p>oleic ester of anhydromannitol 14% and of PEG * 500</p> <p>Saponification index 15 Refraction index 1.461 Viscosity 25 mPas</p> <p>the vaccine (at 20.degree. C.) Type E/H/E Particle size <1 .mu.m</p> <p>Viscosity 50 mPas Stability 4.degree. C. >12 months</p>	<p>PHYSICO-CHEMICAL CHARACTERISTICS</p> <p>Characteristics of the fluid mineral oil 86%</p> <p>COMPOSITION index 18</p> <p>Conductivity 1.0 mS</p> <p>* PEG : polyethyleneglycol</p>
---	--

Detailed Description Paragraph Table (8):

TABLE 4 - 1

CHARACTERISTICS OF THE VACCINES AGAINST AUJESKY'S DISEASE FORMULA 4A % 4B %

CHARACTERISTICS OF ADJUVANT Oil Fluid mineral oil 89% Fluid mineral oil 85%

Emulsifier Oleic acid and mannitol 11% Mannitol and of 15% ester PEG 500 oleic ester

Hydroxyl index 12 Acid index 0.11 0.2 Saponification index 14 17 Refraction index

(25.degree. C.) 1.459 1.460 Viscosity (20.degree. C.) 40 mPas 20 mPas

CHARACTERISTICS OF THE VACCINE Type W/O W/O/W Viscosity (20.degree. C.) 25 mPas 112 mPas

Microscopic aspect drops about 1 .mu.m drops 1 .mu.m Conductivity (20.degree. C.) 0.28 .mu.S 1.3

mS Stability at 4.degree. C. >12 months >12 months Antigen titre 10 9 DCP 50/ml 10 9

DCP 50/ml

Detailed Description Paragraph Table (10):

TABLE 5

FORMULA 32 A % 3408 % 26 K %

CHARACTERISTICS OF THE ADJUVANT Oil Mineral and fluid 85% squalane 85% mineral and

fluid 88% Emulsifier lecithin 7.8% Mannitol and PEG oleic ester PEG monooleate 400

oleic ester 400 Mannitol and PEG 15% clear, pale 12% Aspect clear yellow 7.2% clear,

pale yellow yellow Viscosity 20.degree. C. 35 mPas 30 mPas

CHARACTERISTICS OF THE VACCINE Type multi-phase multi-phase multi-phase % adjuvant 50 50 70

Viscosity 30 mPas 100 mPas 150 mPas Conductivity 3 mS 2 mS 1.8 mS Aspect under the <1 .mu.m

1 .mu.m 1 .mu.m microscope (droplet size)

FORMULA

GTAF 56 % V 7401 - 1 % V7401 - 2 %

CHARACTERISTICS OF THE ADJUVANT Oil Ground-nut oil 92% mineral oil + ground-nut 84%

mineral oil + 87% oil (1:1) ground-nut oil (1:1) Emulsifier copolymer OE/OP 8% oleic

acid and mannitol 16% mannitol and oleic 13% ester acid ester + lecithin Aspect pale

yellow clear, pale yellow clear, yellow Viscosity 50 mPas 45 mPas 50 mPas

CHARACTERISTICS OF THE VACCINE Type multi-phase multi-phase multi-phase % additive 65

64 60 Viscosity 1800 mPas 450 mPas 100 mPas Conductivity 1.9 mS 2 mS 2 mS Microscopic
1 .mu.m 1 .mu.m 1 .mu.m aspect (droplet size)

WEST

Generate Collection

Print

L6: Entry 14 of 26

File: USPT

DOCUMENT-IDENTIFIER: US 5716637 A

TITLE: Solid fat nanoemulsions as vaccine delivery vehicles

Detailed Description Text (120):

To a round 0.5 liter round-bottomed flask, 1.75 gr of egg-lecithin, 1.75 gr of tricaprln, 70 mg of cholesterol, 70 mg of oleic acid, and 7 mg of tocopherol succinate were added. The lipid mixture was dissolved in 50 ml of chloroform. The organic solvent was evaporated until complete dryness under reduced pressure using a rotary evaporator (Heidolph, Germany). To the dry lipid film 60 ml of aqueous solution containing 0.1% EDTA were added and the mixture was then hydrated by shaking or 30 min. using a multiwrist shaker (Labline, U.S.A.) until all the lipids were homogeneously dispersed in the aqueous phase. The dispersion was homogenized using a Microlab 70 Gaulin Homogenizer (5 cycles at 800 bar). The particle size distribution of the resultant emulsomes was determined using a N4MD Coulter Particle Size Analyzer (Coulter Electronics, England). The indicated the existence of a single homogeneous population of emulsomes with a mean particle diameter of 140.+-.50 nm. Then 6.72 gr of a 1% Carbopol solution was added and stirred for 20 min to confer mucoadhesive properties to the emulsome preparation. Glycerol (1.44 gr) were added thereafter to reach a physiological osmolarity (269 mOsm). The pH was adjusted to 6.0 using a 1M NaOH solution. To this plain mucoadhesive emulsome preparation, antigens can be added extrinsically and mixed with the emulsome carrier particles by gentle shaking in order to obtain the proper emulsome vaccine.

Detailed Description Text (123):

To a round 0.25 liter round-bottomed flask, 2.5 gr of egg-lecithin, 2.5 gr of tricaprln, 100 mg of cholesterol, 100 mg of oleic acid, and 10 mg of tocopherol succinate were added. The lipid mixture was dissolved in 25 ml of chloroform. The organic solvent was evaporated until complete dryness under reduced pressure using a rotary evaporator (Heidolph, Germany). To the dry lipid film 60 ml of phosphate buffered saline containing 0.5 mg of Hepatitis B antigen were added and the mixture was then hydrated by shaking for 30 min using a Multiwrist shaker (Labline, U.S.A.) until all the lipids were homogeneously dispersed in the aqueous phase. The dispersion was homogenized using a Microlab 70 Gaulin Homogenizer (5 cycles at 800 bar). The particle size distribution of the resultant emulsomes was determined using a N4MD Coulter Particle Size Analyzer (Coulter Electronics, England). The differential weight % mode of the instrument indicated the existence of a single homogeneous population of emulsomes with a mean particle diameter of 105+24 nm. The emulsome vaccine formulation was then 2-fold concentrated using a Filtron ultrafiltration stirred cell (Omega Series membrane with 10,000 molecular weight cutoff, Filtron Technology Corp., Massachusettes).

Detailed Description Text (128):

To a round 0.25 liter round-bottomed flask, 0.24 gr of egg-lecithin, 0.24 gr of tricaprln, 20 mg of cholesterol, and 20 mg of oleic acid, and 2 mg of tocopherol succinate were added. The lipid mixture was dissolved in 50 ml of chloroform. The organic solvent was evaporated until complete dryness under reduced pressure using a rotary evaporator (Heidolph, Germany). To the dry lipid film 60 ml of aqueous solution containing 0.18 mg of gp160 antigen and 0.1% EDTA were added and the mixture was then hydrated by shaking for 30 min. using a multiwrist shaker (Labline, U.S.A.) until all the lipids were homogeneously dispersed in the aqueous phase. The dispersion was homogenized using a Microlab 70 Gaulin Homogenizer (6 cycles at 800 bar). The particle size distribution of the resultant emulsomes was determined using

a N4MD Coulter Particle Size Analyzer (Coulter Electronics, England). The differential weight % mode of the instrument indicated the existence of a single homogeneous population of emulsomes with a mean particle diameter of 158.+-.57 nm. The emulsome vaccine formulation was then 5-fold concentrated using a Filtron ultrafiltration stirred cell (Omega Series membrane with 10,000 molecular weight cutoff, Filtron Technology Corp., Massachusetts). Then 1.3 gr of a 1% Carbopol solution was added and stirred for 15 min to confer mucoadhesive properties to the emulsome vaccine preparation. Glycerol (0.285 gr) were added thereafter to reach a physiological osmolarity. The pH was adjusted to 6.0 using a 0.5M NaOH solution. The estimated final gp160 concentration in the formulation was 15 .mu.g/ml.

Detailed Description Text (161):

To a round 0.25 liter round-bottomed flask, 0.4 gr of egg-lecithin, 0.4 gr of tricaprin, 15 mg of cholesterol, and 15 mg of oleic acid, and 1.5 mg of tocopherol succinate were added. The lipid mixture was dissolved in 50 ml of chloroform. The organic solvent was evaporated until complete dryness under reduced pressure using a rotary evaporator (Heidolph, Germany). To the dry lipid film 50 ml of aqueous solution containing 80 .mu.g of LC-467 Leishmania lipopeptide antigen in phosphate buffered saline were added and the mixture was then hydrated by shaking for 30 min. using a multiwrist shaker (Labline, U.S.A.) until all the lipids were homogeneously dispersed in the aqueous phase. The dispersion was homogenized using a Microlab 70 Gaulin Homogenizer (5 cycles at 800 bar). The particle size distribution of the resultant emulsomes was determined using a N4MD Coulter Particle Size Analyzer (Coulter Electronics, England). The differential weight % mode of the instrument indicated the existence of a single homogeneous population of emulsomes with a mean particle diameter of 181.+-.35 nm. The emulsome vaccine formulations were then 6.5-fold concentrated using a Filtron ultrafiltration stirred cell (Omega Series membrane with 10,000 molecular weight cutoff, Filtron Technology Corp., Massachusetts). The estimated final antigen concentration in the formulation was 0.25 mg/ml.

WEST

Generate Collection

Print

L6: Entry 13 of 26

File: USPT

DOCUMENT-IDENTIFIER: US 5730989 A

TITLE: Oral vaccine against gram negative bacterial infection

Detailed Description Text (3):

The basic process for producing the oral preparation of the invention commences with growth and harvest of the bacteria, inactivation, preferably but not exclusively with formaldehyde, and lyophilization of the whole cells. This process appears to maintain the antigenic integrity of the bacteria. Because of the feculent nature of the cells, the preferred diluent contains an aromatic oil, preferably a peppermint oil or a cherry-flavored oil, encapsulated in a non-phospholipid liposome (Novasome.RTM.) to enhance the palatability of the vaccine. These flavored Novasomes are composed of glycerol monostearate, soya sterols, soybean oil, cherry or peppermint oil, polysorbate 60, oleic acid, and water for injection. Details for preparation of lipid vesicles containing oil are disclosed in U.S. Pat. No. 4,911,928, the disclosure of which is incorporated herein by reference. However, other materials constituting the lipid vesicles, and other production methods, could be used so long as the flavor masking provision is met. An additional advantage of using the lipid vesicles described herein is that these vesicles appear to provide adjuvant activity in addition to their flavor masking capability. While such adjuvant activity is not necessary for practice of the invention, it may raise antibody titers, as described in U.S. Ser. No. 08/201,346, entitled "Vaccines Containing Paucilamellar Lipid Vesicles as Immunological Adjuvants", incorporated herein by reference.

Detailed Description Text (7):

The Novasome-WFI diluent is a paucilamellar, non-phospholipid liposome containing cherry-flavored oil to enhance the palatability of the E. coli 0157:H7 vaccine. This Novasome preparation is composed of glycerol monostearate (7.9%), soya sterols (2.2%), soybean oil (9.2%), cherry oil (4.5%), polysorbate 60 (2.1%), oleic acid (0.1%) and water for injection (74%). After production of the Novasome lipid vesicles, they are diluted with WFI in a ratio of Novasomes:WFI of 1:32 (v/v). The final percentage of water in the Novasome-WFI diluent is 99.2%. The resultant Novasome-WFI diluent is a sterile Novasome suspension in water for injection in a single use vial. The Novasome-WFI diluent is stored at room temperature. Ten milliliters of the Novasome-WFI diluent are utilized to reconstitute each bottle of the E. coli 0157:H7 vaccine.

WEST

Generate Collection

Print

L6: Entry 12 of 26

File: USPT

DOCUMENT-IDENTIFIER: US 5739118 A

TITLE: Compositions and methods for delivery of genetic material

Detailed Description Text (71):

Examples of anionic lipids useful as genetic vaccine facilitators include the salts of lauric and oleic acids, as well as lauric and oleic acids, sulfated alcohols which are neutralized sulfuric acid, acid esters of lauryl and cetyl alcohol, including sodium lauryl sulfate and alkyl polyoxyethylene sulfates. Sulfonates such as dioctyl sodium sulfosuccinate may also be used. The potassium, sodium and ammonium salts of lauric and oleic acids are soluble in water and are good oil/water emulsifying agents. The calcium, magnesium, and aluminum salts of these fatty acids are water insoluble and result in water/oil emulsions. These compounds are pharmaceutical necessities which are widely used in ointments, tooth powders, and various other pharmaceutical preparations as emulsifying agents, detergents, and wetting agents. Examples of such genetic vaccine facilitating agents of the invention are sodium laurate, potassium laurate, sodium lauryl sulfate, potassium lauryl sulfate, ammonium lauryl sulfate, lauric acid, oleic acid, dioctyl sodium sulfosuccinate. Preferred genetic vaccine facilitators are sodium lauryl sulfate and oleic acid.

Detailed Description Text (73):

Oleic acid N.F. consists chiefly of (Z)-9-octadecenoic acid together with variable amounts of other fatty acids such as linolenic and steric acids. Oleic acid preparations may be formulated for parenteral administration as a genetic vaccine facilitating agent containing 0.1 mg to 100 mg oleic acid per ml, preferably 1.0 mg to 10 mg, in a pharmaceutically acceptable carrier, preferably sterile water for injection, or sodium chloride injection, or another pharmaceutically acceptable aqueous injection fluid. Other doses and concentrations which achieve the desired facilitation of the effect of the genetic construct may be used. For this application oleic acid is injected into the site of administration of the genetic construct, either before, after, and/or simultaneously, preferably simultaneously, with the administration of the genetic construct.

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 26 of 26 returned.**☐ 1. Document ID: US 6369201 B1

L6: Entry 1 of 26

File: USPT

US-PAT-NO: 6369201

DOCUMENT-IDENTIFIER: US 6369201 B1

TITLE: Myostatin multimers

DATE-ISSUED: April 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barker; Christopher A.	Saskatoon			CA
Morsey; Mohamad	Niantic	CT		

US-CL-CURRENT: [530/387.1](#); [435/320.1](#), [435/69.7](#), [530/350](#), [530/351](#), [530/399](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 2. Document ID: US 6235282 B1

L6: Entry 2 of 26

File: USPT

US-PAT-NO: 6235282

DOCUMENT-IDENTIFIER: US 6235282 B1

TITLE: Vaccinal fluid water-in-oil emulsions containing a metabolizable oil

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Riviere; Michel Emile Albert	Ecully			FR
Roulet; Claude	Venissieux			FR

US-CL-CURRENT: [424/184.1](#); [424/1.11](#), [424/190.1](#), [424/191.1](#), [424/192.1](#), [424/193.1](#), [424/199.1](#), [424/200.1](#), [424/201.1](#), [424/278.1](#), [424/283.1](#), [514/785](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMIC
Draw Desc	Image										

☐ 3. Document ID: US 6197755 B1

L6: Entry 3 of 26

File: USPT

US-PAT-NO: 6197755

DOCUMENT-IDENTIFIER: US 6197755 B1

TITLE: Compositions and methods for delivery of genetic material

DATE-ISSUED: March 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carrano; Richard A.	Paoli	PA		
Wang; Bin	Haidian			CN
Weiner; David B.	Merion	PA		

US-CL-CURRENT: 514/44; 424/278.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 6187584 B1

L6: Entry 4 of 26

File: USPT

US-PAT-NO: 6187584

DOCUMENT-IDENTIFIER: US 6187584 B1

TITLE: Products and processes for regulation of gene recombination

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dreyfus; David H.	Denver	CO		
Gelfand; Erwin W.	Englewood	CO		

US-CL-CURRENT: 435/320.1; 536/23.1, 536/23.4, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 5. Document ID: US 6080725 A

L6: Entry 5 of 26

File: USPT

US-PAT-NO: 6080725

DOCUMENT-IDENTIFIER: US 6080725 A

TITLE: Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof

DATE-ISSUED: June 27, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Marciani; Dante J.	Birmingham	AL		

US-CL-CURRENT: 514/26; 424/184.1, 514/25, 536/4.1, 536/5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 6. Document ID: US 5962428 A

L6: Entry 6 of 26

File: USPT

US-PAT-NO: 5962428

DOCUMENT-IDENTIFIER: US 5962428 A

TITLE: Compositions and methods for delivery of genetic material

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carrano; Richard A.	Paoli	PA		
Wang; Bin	Haidian			CN
Weiner; David B.	Merion	PA		

US-CL-CURRENT: 514/44; 424/278.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 7. Document ID: US 5959074 A

L6: Entry 7 of 26

File: USPT

US-PAT-NO: 5959074

DOCUMENT-IDENTIFIER: US 5959074 A

TITLE: Products and processes for regulation of gene recombination

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dreyfus; David H.	Denver	CO		
Gelfand; Erwin W.	Englewood	CO		

US-CL-CURRENT: 530/300; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 8. Document ID: US 5888513 A

L6: Entry 8 of 26

File: USPT

US-PAT-NO: 5888513

DOCUMENT-IDENTIFIER: US 5888513 A

TITLE: Recombinant PRRSV proteins, diagnostic kits and vaccines containing such recombinant PRRSV proteins

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Plana Duran; Juan	Vall de Bianya			ES
Casal Alvarez; Jose Ignacio	Madrid			ES
Climent Sanchez; Isabel	Vall de Bianya			ES

US-CL-CURRENT: 424/186.1; 424/198.1, 424/199.1, 424/201.1, 424/204.1, 424/278.1, 424/815, 435/235.1, 435/239, 435/252.3, 435/325, 435/5, 435/69.3, 435/91.1, 530/350, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KUMC
Draw Desc	Image									

☐ 9. Document ID: US 5837249 A

L6: Entry 9 of 26

File: USPT

US-PAT-NO: 5837249

DOCUMENT-IDENTIFIER: US 5837249 A

TITLE: Method for generating an immunogenic T cell response protective against a virus

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heber-Katz; Ellen	Philadelphia	PA		
Dietzschold; Bernhard	Newtown Square	PA		

US-CL-CURRENT: 424/186.1; 424/185.1, 424/196.11, 424/224.1, 424/229.1, 424/231.1, 530/323, 530/326

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KUMC
Draw Desc	Image									

☐ 10. Document ID: US 5814321 A

L6: Entry 10 of 26

File: USPT

US-PAT-NO: 5814321

DOCUMENT-IDENTIFIER: US 5814321 A

TITLE: Oil adjuvant vaccine and method for preparing same

DATE-ISSUED: September 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miyahara; Tokuji	Kumamoto-ken			JP
Takase; Kozo	Kumamoto-ken			JP
Saito; Koichi	Amagasaki			JP
Kishimoto; Yoko	Akashi			JP
Tokuyama; Satoru	Nishinomiya			JP

US-CL-CURRENT: [424/278.1](#); [424/283.1](#), [514/937](#), [514/938](#), [514/939](#), [514/943](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 11. Document ID: US 5744137 A

L6: Entry 11 of 26

File: USPT

US-PAT-NO: 5744137

DOCUMENT-IDENTIFIER: US 5744137 A

TITLE: Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stone; Henry D.	Winterville	GA		

US-CL-CURRENT: [424/184.1](#); [424/214.1](#), [424/455](#), [424/70.11](#), [424/70.31](#), [514/937](#), [514/938](#), [514/939](#), [514/943](#), [525/292](#), [525/323](#), [525/331.7](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 12. Document ID: US 5739118 A

L6: Entry 12 of 26

File: USPT

US-PAT-NO: 5739118

DOCUMENT-IDENTIFIER: US 5739118 A

TITLE: Compositions and methods for delivery of genetic material

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carrano; Richard A.	Paoli	PA		
Wang; Bin	Beijing			CN
Weiner; David B.	Merion	PA		

US-CL-CURRENT: 514/44; 424/184.1, 424/278.1, 435/375, 435/69.1, 435/69.3, 514/25,
514/27, 514/33, 514/35, 514/510, 514/54, 514/680, 514/731, 514/732

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 13. Document ID: US 5730989 A

L6: Entry 13 of 26

File: USPT

US-PAT-NO: 5730989

DOCUMENT-IDENTIFIER: US 5730989 A

TITLE: Oral vaccine against gram negative bacterial infection

DATE-ISSUED: March 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wright; D. Craig	Gaithersburg	MD		

US-CL-CURRENT: 424/241.1; 424/197.11, 424/249.1, 424/255.1, 424/258.1, 424/261.1,
424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 14. Document ID: US 5716637 A

L6: Entry 14 of 26

File: USPT

US-PAT-NO: 5716637

DOCUMENT-IDENTIFIER: US 5716637 A

TITLE: Solid fat nanoemulsions as vaccine delivery vehicles

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anselem; Shimon	Rehovot			IL
Lowell; George H.	Baltimore	MD		
Aviv; Haim	Rehovot			IL
Friedman; Doron	Carmei Yosef			IL

US-CL-CURRENT: 424/450; 424/184.1, 424/188.1, 424/204.1, 424/208.1, 424/234.1,
424/236.1, 424/237.1, 424/269.1, 424/489, 424/490, 424/502, 428/937, 514/937

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 15. Document ID: US 5668170 A

L6: Entry 15 of 26

File: USPT

US-PAT-NO: 5668170

DOCUMENT-IDENTIFIER: US 5668170 A

TITLE: Composition and method enhancing transdermal electrotransport agent delivery

DATE-ISSUED: September 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gyory; J. Richard	San Jose	CA		

US-CL-CURRENT: 514/449; 424/78.1, 514/48, 604/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 16. Document ID: US 5424067 A

L6: Entry 16 of 26

File: USPT

US-PAT-NO: 5424067

DOCUMENT-IDENTIFIER: US 5424067 A

TITLE: Injectable multi-phase emulsions

DATE-ISSUED: June 13, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brancq; Bernard	Le Chesnay			FR
Trouve; Gerard	Castres			FR

US-CL-CURRENT: 424/184.1; 424/278.1, 514/785

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 17. Document ID: US 5352450 A

L6: Entry 17 of 26

File: USPT

US-PAT-NO: 5352450

DOCUMENT-IDENTIFIER: US 5352450 A

TITLE: Method for preparing vaccine for dental caries and vaccinal compositions for

dental caries used as nasal drop

DATE-ISSUED: October 4, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koga; Toshihiko	Tokyo			JP
Okahashi; Nobuo	Komae			JP
Takahashi; Ichiro	Yokohama			JP
Shibuya; Koji	Kanagawa			JP
Ohta; Hirotaka	Kanagawa			JP

US-CL-CURRENT: 424/190.1; 424/242.1, 424/244.1, 435/252.3, 435/69.1, 435/71.2,
530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 18. Document ID: JP 10218788 A JP 10218788 A

L6: Entry 18 of 26

File: JPAB

Aug 18, 1998

PUB-NO: JP410218788A

DOCUMENT-IDENTIFIER: JP 10218788 A

TITLE: PRODUCTION OF IMMUNOPOTENTIATOR AND IMMUNOPOTENTIATION

PUBN-DATE: August 18, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
NISHIMURA, MASAOKI	

INT-CL (IPC): A61 K 39/00; A61 K 9/107; A61 K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	K00C
Draw Desc	Image									

☐ 19. Document ID: JP 63035525 A JP 63035525 A

L6: Entry 19 of 26

File: JPAB

Feb 16, 1988

PUB-NO: JP363035525A

DOCUMENT-IDENTIFIER: JP 63035525 A

TITLE: VACCINE FOR ANIMAL

PUBN-DATE: February 16, 1988

INVENTOR-INFORMATION:

NAME
SASAKI, FUMIARI
NAKAI, MASAHIKA
KODAMA, KAZUO
IWAMOTO, ICHIZO
HIRAMATSU, KAZUHISA
AJIKI, MASAYUKI
OGIYA, TOSHIKI
OKABE, TATSUJI

COUNTRY

INT-CL (IPC): A61K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 20. Document ID: RU 2058154 C1

L6: Entry 20 of 26

File: DWPI

Apr 20, 1996

DERWENT-ACC-NO: 1997-041014

DERWENT-WEEK: 199704

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Water-in-oil emulsion adjuvant compsn for livestock vaccines - contg
emulsifier comprising prod obtd by esterifying mixt of oleic and stearic acids with
poly:glycerine

INVENTOR: DUDNIKOV, A I; MAMKOV, N S ; MIKHALISHIN, V V

PRIORITY-DATA: 1992RU-0012922 (December 21, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
RU 2058154 C1	April 20, 1996		007	A61K039/135

INT-CL (IPC): A61 K 39/135

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 21. Document ID: CA 2046893 C WO 9007924 A AU 9051056 A US 5000960 A

L6: Entry 21 of 26

File: DWPI

Nov 7, 2000

DERWENT-ACC-NO: 1990-253849

DERWENT-WEEK: 200061

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Lipsome(s) linked to targetting mols - through di:sulphide bond

INVENTOR: WALLACH, D F H

PRIORITY-DATA: 1989US-0300079 (January 19, 1989), 1987US-0025525 (March 13, 1987),
1987US-0078658 (July 28, 1987), 1987US-0124824 (November 24, 1987), 1988US-0157571
(March 3, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CA 2046893 C	November 7, 2000	E	000	A61K009/127
WO 9007924 A	July 26, 1990		028	
AU 9051056 A	August 13, 1990		000	
US 5000960 A	March 19, 1991		000	

INT-CL (IPC): A61K 9/12; A61K 9/127; A61K 37/22; A61K 38/00; A61K 39/44; A61K 49/00; B01J 13/02

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 22. Document ID: WO 9006747 A CA 2006251 A AU 9049446 A US 5019392 A EP 449983 A BR 8907837 A JP 04503353 W AU 633540 B EP 449983 A4

L6: Entry 22 of 26

File: DWPI

Jun 28, 1990

DERWENT-ACC-NO: 1990-224366

DERWENT-WEEK: 199739

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Liposome compsns. for pest or parasite control - contg. water-insol. active agent in paucilamellar lipid vesicles

INVENTOR: WALLACH, D F H; WALLACH, D

PRIORITY-DATA: 1988US-0286731 (December 20, 1988), 1987US-0025525 (March 13, 1987), 1987US-0078658 (July 28, 1987), 1987US-0124824 (November 24, 1987), 1988US-0157571 (March 3, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9006747 A	June 28, 1990		000	
CA 2006251 A	June 20, 1990		000	
AU 9049446 A	July 10, 1990		000	
US 5019392 A	May 28, 1991		000	
EP 449983 A	October 9, 1991		000	
BR 8907837 A	October 22, 1991		000	
JP 04503353 W	June 18, 1992		008	A01N025/28
AU 633540 B	February 4, 1993		000	A61K009/127
EP 449983 A4	September 30, 1992		000	

INT-CL (IPC): A01N 25/00; A01N 25/04; A01N 25/28; A61K 9/127; A61K 9/66; A61K 37/22; B01J 13/02

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 23. Document ID: WO 9001921 A US 4942038 A AU 8940689 A CA 1332153 C

L6: Entry 23 of 26

File: DWPI

Mar 8, 1990

DERWENT-ACC-NO: 1990-099242

DERWENT-WEEK: 199605

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Humectant for use in external animal care prods. - comprising moisturiser encapsulated in paucilamellar lipid vesicle

INVENTOR: WALLACH, D F H

PRIORITY-DATA: 1988US-0234309 (August 19, 1988), 1987US-0025525 (March 13, 1987), 1987US-0078658 (July 28, 1987), 1987US-0124824 (November 24, 1987), 1988US-0157571 (March 3, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9001921 A	March 8, 1990	E	018	
US 4942038 A	July 17, 1990		000	
AU 8940689 A	March 23, 1990		000	
CA 1332153 C	September 27, 1994		000	A61K007/08

INT-CL (IPC): A61K 7/07; A61K 7/075; A61K 7/08; A61K 9/66; A61K 37/22; B01J 13/02; C09K 3/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 24. Document ID: JP 63035525 A JP 94081731 B2

L6: Entry 24 of 26

File: DWPI

Feb 16, 1988

DERWENT-ACC-NO: 1988-081779

DERWENT-WEEK: 198812

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Low viscosity, stable vaccine for animals - contains water-in-oil hydrophilic oily adjuvant comprising anhydro mannitol oleic ester surfactant and liq. paraffin

PRIORITY-DATA: 1986JP-0182400 (July 31, 1986)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 63035525 A	February 16, 1988		007	
JP 94081731 B2	October 19, 1994		007	A61K039/39

INT-CL (IPC): A61K 39/39

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 25. Document ID: FR 2501526 A

L6: Entry 25 of 26

File: DWPI

Sep 17, 1982

DERWENT-ACC-NO: 1982-93179E

DERWENT-WEEK: 198244

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Emulsifier for veterinary oily vaccine prodn. - is alkoxylated oleic acid ester of mannitol dehydration prod.

INVENTOR: BRANCQ, B; DELAFAIRE, P

PRIORITY-DATA: 1981FR-0005119 (March 13, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
FR 2501526 A	September 17, 1982		011	

INT-CL (IPC): A61K 9/10; A61K 39/00; B01F 17/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 26. Document ID: SU 827543 B

L6: Entry 26 of 26

File: DWPI

May 7, 1981

DERWENT-ACC-NO: 1982-15437E

DERWENT-WEEK: 198208

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Nutrient medium for vaccine strains of brucella - contg. agar, aminoacid(s), glucose, vitamin(s), mineral salts, citric and lactic acids, DNA hydrolysate and poly-mannitol oleate

INVENTOR: ABUASHVILI, N M; BIRKADZE, T V ; KIKALISHVI, V N

PRIORITY-DATA: 1979SU-2743064 (March 29, 1979)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
SU 827543 B	May 7, 1981		002	

INT-CL (IPC): C12N 1/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

Generate Collection

Print

Terms

Documents

oleic same vaccine\$

26

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)

WEST Search History

DATE: Thursday, August 15, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L6	oleic same vaccine\$	26	L6
L5	oleic adj1 acid same vaccine\$	21	L5
L4	monoglyceride\$ same vaccine\$	5	L4
L3	monoglyceride\$ adj10 vaccine\$	0	L3
L2	monoglyceride\$ adj10 adjuvant\$	16	L2
L1	monoglyceride\$ adj5 adjuvant\$	12	L1

END OF SEARCH HISTORY